/Vertex%20Pharmaceuticals%20logo%20By%20Midea.jpeg)
Vertex Pharmaceuticals Incorporated (VRTX), with a market capitalization of approximately $123.2 billion, is a prominent biotechnology company headquartered in Boston. It discovers, develops, and commercializes innovative medicines for serious diseases, focusing on specialty markets through scientific research and development.
VRTX is set to report its Q3 earnings on Monday, November 2, 2026, after the market closes. Wall Street anticipates diluted EPS of $4.28, a 1.4% increase from $4.22 in the same quarter last year. Notably, the company has topped analysts’ EPS expectations in each of the past four quarters.
